Findings

What do systematic reviews say?

7 questions · 9 findings · 5 reviews · Gut

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 22.2%Moderate 4 · 44.4%High 2 · 22.2%

Failure to maintain remission · Participants with Crohn's disease in remission

Adalimumab leads to lower failure to maintain clinical remission compared with placebo (high certainty).

2 findings from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
RR 0.7 [0.64, 0.77]
3 studies · 683 participants
High
Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
RR 0.66 [0.52, 0.83]
2 studies · 554 participants
Moderate

Failure to maintain remission · Patients with active Crohn's disease

Antibiotic showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).

1 finding from 1 review

Antibiotics for induction and maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.87 [0.52, 1.47]
2 studies · 155 participants
Low

Failure to maintain remission · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for induction and maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Failure to maintain remission · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).

2 findings from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.8 [0.63, 1.02]
1 study · 145 participants
Moderate
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.76 [0.64, 0.91]
1 study · 388 participants
Moderate

Failure to maintain remission · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.84 [0.58, 1.2]
1 study · 99 participants
Low

Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.68 [0.61, 0.76]
8 studies · 1555 participants
High

Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate